Neuroleptic discontinuation during dementia care: A recent trial and its implications for practice

Research output: Contribution to journalShort survey

Abstract

This Practice Point commentary discusses the DART-AD trial, a prospective study investigating neuroleptic discontinuation. Patients with dementia of the Alzheimer type who were in residential care and taking neuroleptics for 3 months or longer, were randomized to receive one of two 12-month interventions: continuation or discontinuation of neuroleptic treatment. The primary aim was to determine whether neuroleptic discontinuation improves cognitive outcomes. After 6 months, neuroleptic discontinuation was not detrimental to cognition or function in patients with Alzheimer's disease, except for those who had Neuropsychiatric Inventory scores ≥15 at enrollment (these patients had even higher Neuropsychiatric Inventory scores at 12 months). This commentary highlights methodological issues pertinent to the translation of these results and also considers implications for everyday practice. From a practice perspective, it would seem that judicious prescribing and timely discontinuation might optimize the risk-benefit balance of neuroleptics.

Original languageEnglish (US)
Pages (from-to)528-529
Number of pages2
JournalNature Clinical Practice Neurology
Volume4
Issue number10
DOIs
StatePublished - Aug 27 2008

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Neuroleptic discontinuation during dementia care: A recent trial and its implications for practice'. Together they form a unique fingerprint.

  • Cite this